Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2009-09-04 Regulatory Filings
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2009
Regulatory Filings
2009-09-04 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a letter from the company's securities counsel responding to comments from the SEC staff regarding a post-effective amendment on Form S-1. It references filing amendments and correspondence with the SEC, specifically about registration statements and disclosures related to shares. The document is a regulatory correspondence and does not contain financial statements, management discussion, or report data. It is not a full report but a regulatory filing related to securities registration and amendments. The document length is short (2681 characters) and is primarily a response letter to the SEC. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other specific categories.
2009-09-03 English
POS AM
Capital/Financing Update Classification · 100% confidence The document is a Post-Effective Amendment No. 3 to Form S-1 filed with the SEC, which is a registration statement under the Securities Act of 1933. It includes detailed information about the registration of securities, private placements, warrants, and selling stockholders. The document is not an earnings release, annual report, or other financial report but rather a regulatory filing related to capital raising and securities registration. The presence of detailed offering terms, use of proceeds, and registration statement references confirms this is a Capital/Financing Update filing. The document length is substantial and contains substantive information about securities offerings and related transactions, consistent with the CAP category.
2009-09-03 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering by Oculus Innovative Sciences, Inc. It includes extensive information about the company, the offering, risk factors, use of proceeds, and regulatory considerations. The presence of terms like 'Prospectus Supplement', 'Rule 424(b)(5)', and detailed offering information indicates this is a capital raising document. It is not an annual report, earnings release, or management discussion, nor is it a regulatory filing unrelated to financing. The document is clearly about a securities offering and capital raising activity, which fits the definition of a Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the actual prospectus supplement, not just an announcement of a filing. Therefore, the correct classification is CAP with high confidence.
2009-09-02 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a letter from the company's Vice President and General Counsel to the SEC, acknowledging comments from the SEC staff regarding a post-effective amendment on Form S-1. It is a correspondence related to regulatory review and compliance, not a financial report or announcement of financial results. The document is short (1584 characters) and does not contain financial data or detailed report content. It is a regulatory communication responding to SEC comments, fitting the category of Regulatory Filings (RNS).
2009-09-02 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a letter from the securities counsel of Oculus Innovative Sciences, Inc. responding to comments from the SEC staff regarding a Post-effective amendment on Form S-1. It discusses registration statements, prospectus amendments, and responses to SEC comments. There are no financial statements, earnings data, or detailed financial analysis present. The document is primarily correspondence related to regulatory filings and amendments to registration statements, not a financial report or earnings release. The length is under 5,000 characters and it is a letter responding to SEC comments, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous regulatory correspondence and filings that do not fit other categories.
2009-08-27 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.